Clinicopathologic consequences following discontinuation of rifaximin in patients with sickle cell disease. Lim SH, Dutta D. Am J Hematol 2020;95:E151-E153.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Lim SH, Dutta D. Clinicopathologic consequences following discontinuation of rifaximin in patients with sickle cell disease. Am J Hematol 2020;95:E151-E153.
PMID: 32243610